# Trade Mark Journal No.2026/011 13 March 2026

## WO0000001887944 (5,44)

Office of origin: United States of America

Date of International Registration:6 October 2025
Date of designation in the UK: 6 October 2025

The PLUS symbol in the trade mark shall be reproduced neither in white on a red background nor in red on a white background; nor shall it be reproduced in any other colour likely to be confused with the Swiss cross or the emblem of the Red Cross.

International priority date claimed: 11 April 2025 (United States of America) (99133260)

Class 5
  Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immunological disorders; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of graft versus host disorder (GVHD); pharmaceutical preparations for the treatment of hematological disorders; pharmaceutical preparations for the treatment of hypophosphatemia disorders; pharmaceutical preparations for the treatment of myeloproliferative disorders; pharmaceutical preparations for the treatment of skeletal or chondrocyte disorders; pharmaceutical preparations for the treatment of dermatological disorders; pharmaceutical preparations for the treatment of fibrotic disorders.
Class 44
  Providing medical information via a website.

Incyte Holdings Corporation

Representative: Page, White & Farrer Limited, Bedford House, John Street London WC1N 2BF UNITED KINGDOM